Transseptal Access Systems Market

Transseptal Access Systems Market Outlook (2023-2033)

Worldwide revenue from the transseptal access systems market stands at US$ 941.3 Mn in 2022, with the global market estimated to expand at a CAGR of 7.3% to reach US$ 2.1 Bn by the end of 2033.

As assessed by Persistence Market Research, the transseptal access sheath contributed the largest share of 86.0% among the product category in 2022. The transseptal access systems market holds 67.2% of the global left atrial appendage closure devices market valued at US$ 1.4 Bn in 2022.

Sales Analysis of Transseptal Access Systems Market from 2012 to 2022 Vs Market Outlook for 2023 to 2033

The global transseptal access systems market recorded a historic CAGR of 9.0% in the last 10 years from 2012 to 2022.

It is becoming more popular to catheterize the left atrium in order to perform arrhythmia ablation through a transseptal puncture employing transseptal access methods. The number of cardiac patients is growing as a result of the ageing population's increased risk of diseases like hypertension. In addition, consumption of alcohol, tobacco, and changes in lifestyle are frequently cited as contributing factors to disorders like atrial fibrillation.

Due to the increasing prevalence of atrial fibrillation in both developed and developing countries, effective atrial fibrillation treatments such atrial fibrillation ablation therapy, mitral valve replacement, and LLA occlusion therapy are necessary.

Additionally, during the projected period, there will be numerous chances for market expansion due to advancements in healthcare infrastructure in emerging nations.

The global market for transseptal access systems is expected to grow steadily over the coming years as a result of the introduction of cutting-edge treatments, such as left trial appendage occlusion therapy, which has benefited many patients.

Due to the advent of novel technologies, such as left trial appendage occlusion therapy, which has benefited many patients, it is anticipated that the global market for transseptal access systems would expand steadily over the next years.

How do Manufacturers Promote Market Expansion?

“Increasing Risk Factors like Hypertension and Growing Product Penetration

Transseptal access systems' increasing technological development and rising levels of public awareness are anticipated to increase demand. Transseptal puncture methods have advanced due to the introduction of transesophageal and fluoroscopic echocardiographic pictures.

Similarly, it is anticipated that improvements in mechanical technology and the introduction of new products with improved features would drive an increase in demand for transseptal access systems.

For instance,

• The introduction AVANCE Bi-directional steerable introducer sheaths by Abbott, which have even bendable properties in all directions, makes it easier to enter the left atrium during transseptal accessibility, improving procedure efficiency.

Leading producers of transseptal access systems are collaborating to increase product penetration in developing regions. Numerous causes, including an ageing general population and inadequate management of risk factors like hypertension, are driving up the patient population.

In addition to health problems, other risk factors for atrial fibrillation include the consumption of alcohol, tobacco, and other drugs, as well as a changing culture that promotes an active lifestyle.

It is anticipated that in the projected years, the government and commercial healthcare insurance providers would support the expansion of the global market, who have made it easier to receive reimbursement for the treatment and diagnosis of diseases.

Consumers' changing lifestyles as a result of their hectic lifestyles have led to high-risk conditions that might cause atrial fibrillation, which is projected to increase in prevalence globally and accelerate market growth in the upcoming years.

Is There Any Way the Market's Growth Could Be Impacted?

“Shortage of Skilled Professionals and Lack of Availability of Enhanced Services”

Global demand for transseptal access systems increased as atrial fibrillation cases increased. However, there is a lack of qualified and skilled professions for these procedures in several middle to low income nations, thus restraining the overall market growth.

Transseptal access system usage is decreased as a result of other obstacles, such as supply chain problems, ineffective healthcare service management, a lack of technologically advanced equipment, etc., which restrains the market growth.

Despite advancements in healthcare facilities and regional and international support, the great majority of people still have limited access to treatment options. Factors include a shortage of qualified workers, substandard service providers, a lack of knowledge of disease symptoms, poverty, problems with the supply chain, ineffective management of healthcare services, a lack of technologically advanced equipment, etc.

These factors limit the trend in product consumption despite the high demand, which restrains the market expansion of transseptal access systems.

Country-wise Insights

Why is The Transseptal Access Systems Market Booming in The U.S.?

“Rising Atrial Fibrillation in the U.S.”

The U.S. is expected to account for a 41.8% share of the global market in 2023 and is projected to experience high growth throughout the forecast period.

As health facilities are expanding and developing, so are the healthcare services. This has improved the quality of life and expanded life expectancy. The global rise in the geriatric age population group is a result of this factor.

Effective healthcare policies in the United States and simple access to a variety of diagnostic and treatment services are further enhancing the market share for transseptal access systems in the country.

• Aged 60 and older made up around 11% of the global population in 2012, according to the United Nations Population Fund. By 2050, this number is projected to rise to 22%.
• According to the Centres for Disease Control and Prevention (CDC), the most frequent arrhythmia identified in medical care is atrial fibrillation. There are estimates of 2.7 million to 6.1 million Americans who have atrial fibrillation. By 2030, this number is projected to increase to 12.1 million. Around 2% of adults under the age of 65 and 9% of people 65 and over have atrial fibrillation.

Why is Germany Emerging as a Prominent Market for Transseptal Access Systems in Europe?

“Rising Surgical Procedures and Availability of Reimbursements”

In 2023, Germany is set to hold 6.8% of the global market share.

Atrial fibrillation operations including LLA occlusion therapy, atrial fibrillation ablation therapy and mitral valve repair are becoming more and more necessary as atrial fibrillation prevalence and incidence rates continue to rise in European countries.

A well-known and often used method for gaining percutaneous access to the left atrium of the heart is transseptal puncture. German Diagnosis-Related Groups (DRG) F50A, F50B, and F50C are frequently linked to cardiac catheter ablation operations. The translation of relative weights into actual payments is one of various policy reforms in Germany that influence all DRG-based hospital payment systems.

Transseptal access systems are required as a result of the rise in surgical procedures requiring transseptal puncture, and the availability of reforms for reimbursement.

Why is China Considered a Lucrative Market for Transseptal Access Systems?

“Technological Advancements and Market Collaborations”

China dominated the East Asia region in 2022 and is expected to grow with a high growth rate of 10.1% over the forecast duration.

The first clinical case utilising Peijia's Highlife TSMVR system for mitral valve replacement technology was successfully completed in China on December 22, 2021. Peijia Medical proved its technical know-how and capacity for worldwide partnership. In December 2020, Peijia Medical and HighLife SAS, a medical device company with headquarters in France, entered into a licence agreement, as a result of which HighLife SAS granted Peijia Medical an exclusive licence to develop, produce, and market a number of proprietary TMVR products in the Greater China region.

Such key developments are likely to advance the growth of the overall market within China, over the forecast duration.

Category-wise Insights

Which Transseptal Access Systems Product is Driving Market Growth?

“Manufactures are Aiming to expand their Product Portfolio”

In 2022, transseptal access sheaths captured a dominant share of around 86.0%. Based on product, the market is segmented into transseptal access needles and transseptal access sheaths.

Growing industrial expansion initiatives, like the purchase of ablation device companies by strong market players to supply novel products and technology, will present excellent chances to gain customers' trust. Key companies in a turbulent industry are anticipated to expand their technology and product offerings through an increase in strategic acquisitions of start-ups.

• Acutus Medical Purchased Rhythm Xience inc. in May 2019. This partnership expanded Acutus' offering to include access, therapy, diagnosis, and rhythm monitoring solutions.
• AcQCross Transseptal System which is a highly Integrated System of Transseptal Crossing Products, was introduced by Acutus Medical in December 2020 after receiving CE Mark and European clearance. The system's goal is to increase safety and effectiveness in any related to spatial left heart access.

How is Atrial Fibrillation Ablation Demand for Transseptal Access Systems in Application?

“Rising Demand for Catheter-based Atrial Fibrillation Ablation”

On the basis of application, the transseptal access systems market is divided into atrial fibrillation ablation, mitral valve repair, and left atrial appendage occlusion segments. Atrial fibrillation ablation held the biggest market share of these sectors in 2022, at 65.0%.

Atrial fibrillation is common in developing and undeveloped countries, demanding the reform of the healthcare system to ensure successful surgical outcomes. Over the past few years, there has been a dramatic rise in the demand for catheter-based atrial fibrillation ablation. Further increases in treatment demand are anticipated due to growing reimbursement and other government initiatives for cardiac patients.

People have been influenced to undergo particular treatments by a number of public health efforts and government programmes to encourage and raise awareness.

For instance,

• National Atrial Fibrillation Awareness Month is celebrated in September, which is regarded as the most effective time for the Heart Rhythm Society to raise awareness for this potentially fatal arrhythmia.

Which End User is Most Preferred for the Transseptal Access Systems Market?

“Hospitals Serve Humanity and are Essential to a Society's Social Welfare.”

In terms of revenue, the hospital sector dominated the global market for transseptal access systems in 2022, the hospital market category held the highest share with over 49.9%.

Cardiovascular operations like catheterizations, angiographies, ablation and valve replacement surgeries all require hospital-based transseptal access methods. Transseptal access systems have a number of advantages over conventional surgical techniques, including quicker recovery times, reduced risk of bleeding, and fewer complications.

The use of the hospital for transseptal access systems is high because operations angiographies, ablation and valve replacement required highly qualified doctors and operation theatres as well which are present in hospitals.

Competitive Landscape

In this market, few manufacturers exist. To enhance their presence in emerging markets, manufacturers are concentrating on expansion.

Both domestic and foreign firms want to promote their goods and services worldwide by using marketing methods such as product launches, channel expansions, hiring more salespeople, or strategic alliances or partnerships with local distributors. Collaboration with local or regional distributors will help international manufacturers enter untapped markets for their products.

• Boston Scientific Corporation announced it had completed the acquisition of Baylis Medical Company Inc. in February 2022. This company provides cutting-edge transseptal access solutions as well as guidewires, sheaths, and dilators used to facilitate catheter-based left-heart procedures.
• The privately held medical device business Cephea Valve Technologies, Inc. develops minimally invasive heart valve replacement solutions for persons with mitral valve disease. In January 2019, Abbott announced that it has exercised its option to purchase the company.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the transseptal access systems market, which are available in the full report.

Transseptal Access Systems Market Report Scope

Key Segments of the Transseptal Access Systems Market

By Product:

• Transseptal Access Needle
• Transseptal Access Sheath

By Application:

• Atrial Fibrillation Ablation
• Mitral Valve Repair
• Left Atrial Appendage Occlusion

By End User:

• Hospitals
• Ambulatory Surgical Centres
• Specialty Clinics

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

To know more about delivery timeline for this report Contact Sales